Unknown

Dataset Information

0

Integrative analysis for the discovery of lung cancer serological markers and validation by MRM-MS.


ABSTRACT: Non-small-cell lung cancer (NSCLC) constitutes approximately 80% of all diagnosed lung cancers, and diagnostic markers detectable in the plasma/serum of NSCLC patients are greatly needed. In this study, we established a pipeline for the discovery of markers using 9 transcriptome datasets from publicly available databases and profiling of six lung cancer cell secretomes. Thirty-one out of 312 proteins that overlapped between two-fold differentially expressed genes and identified cell secretome proteins were detected in the pooled plasma of lung cancer patients. To quantify the candidates in the serum of NSCLC patients, multiple-reaction-monitoring mass spectrometry (MRM-MS) was performed for five candidate biomarkers. Finally, two potential biomarkers (BCHE and GPx3; AUC = 0.713 and 0.673, respectively) and one two-marker panel generated by logistic regression (BCHE/GPx3; AUC = 0.773) were identified. A validation test was performed by ELISA to evaluate the reproducibility of GPx3 and BCHE expression in an independent set of samples (BCHE and GPx3; AUC = 0.630 and 0.759, respectively, BCHE/GPx3 panel; AUC = 0.788). Collectively, these results demonstrate the feasibility of using our pipeline for marker discovery and our MRM-MS platform for verifying potential biomarkers of human diseases.

SUBMITTER: Shin J 

PROVIDER: S-EPMC5570484 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

Integrative analysis for the discovery of lung cancer serological markers and validation by MRM-MS.

Shin Jihye J   Song Sang-Yun SY   Ahn Hee-Sung HS   An Byung Chull BC   Choi Yoo-Duk YD   Yang Eun Gyeong EG   Na Kook-Joo KJ   Lee Seung-Taek ST   Park Jae-Il JI   Kim Seon-Young SY   Lee Cheolju C   Lee Seung-Won SW  

PloS one 20170824 8


Non-small-cell lung cancer (NSCLC) constitutes approximately 80% of all diagnosed lung cancers, and diagnostic markers detectable in the plasma/serum of NSCLC patients are greatly needed. In this study, we established a pipeline for the discovery of markers using 9 transcriptome datasets from publicly available databases and profiling of six lung cancer cell secretomes. Thirty-one out of 312 proteins that overlapped between two-fold differentially expressed genes and identified cell secretome pr  ...[more]

Similar Datasets

| S-EPMC7331696 | biostudies-literature
| S-EPMC2670839 | biostudies-other
| S-EPMC9318382 | biostudies-literature
| S-EPMC4126846 | biostudies-literature
| S-EPMC4963574 | biostudies-literature
| S-EPMC5494096 | biostudies-literature
| S-EPMC11339818 | biostudies-literature
| S-EPMC3934743 | biostudies-literature
| S-EPMC8201988 | biostudies-literature
| S-EPMC6386465 | biostudies-literature